Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population

Journal of Alzheimer's Disease

Volumn 36, Issue 1, 2013, Pages 79-85

  Prins, Niels D ^a   Van Der Flier, Wiesje M ^a,b   Brashear, H Robert ^c   Knol, Dirk L ^b   Van De Pol, Laura A ^a   Barkhof, Frederik ^b   Scheltens, Philip ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Alzheimer's disease; apolipoprotein E; brain infarction; clinical trial; dementia; hippocampus; leukoaraiosis; magnetic resonance imaging; mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E;

AGED; ARTICLE; DEMENTIA; DIGIT SYMBOL CODING TEST; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NEW YORK UNIVERSITY PARAGRAPH RECALL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; TASK PERFORMANCE;

EID: 84878884313     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122233     Document Type: Article

References (29)

1. Petersen RC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 3, 183-194.
2. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 3, 303-308.
3. Huang J, Meyer JS, Zhang Z,Wei J, Hong X,Wang J,Wen H, Wu W,Wu J, Chowdhury MH(2005) Progression of mild cognitive impairment to Alzheimer's or vascular dementia versus normative aging among elderly Chinese. Curr Alzheimer Res 5, 571-578.
4. DeCarli C (2003) Mild cognitive impairment: Prevalence, prognosis, aetiology, and treatment. Lancet Neurol 1, 15-21.
5. Petersen RC (2004) Challenges of epidemiological studies of mild cognitive impairment. Alzheimer Dis Assoc Disord 1, 1-2.
6. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, Jagust W (2004) Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2, 220-227.
7. Nestor PJ, Scheltens P, Hodges JR (2004) Advances in the early detection of Alzheimer's disease. Nat Med 10(Suppl), S34-S41.
8. Jack CRJ, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 7, 1397-1403.
9. Risacher SL, Saykin AJ,West JD, Shen L, Firpi HA, McDonald BC (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 4, 347-361.
10. Staekenborg SS, Koedam EL, Henneman WJ, Stokman P, Barkhof F, Scheltens P, van der Flier WM (2009) Progression of mild cognitive impairment to dementia: Contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 4, 1269-1274.
11. Spampinato MV, Rumboldt Z, Hosker RJ, Mintzer JE (2011) Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology 3, 843-852.
12. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ,Wang D, Brashear HR, Nye JS (2008) Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 22, 2024-2035.
13. Morris JC (1993) The clinical dementia rating (CDR): Current version and scoring rules. Neurology 11, 2412-2414.
14. Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B (1999) Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol 4, 168-179.
15. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 11, 1356-1364.
16. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's disease assessment scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S13-S21.
17. Taylor MJ, Heaton RK (2001) Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc 7, 867-874.
18. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 10, 967-972.
19. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 6, 1318-1322.
20. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C (1999) Threats to applicability of randomised trials: Exclusions and selective participation. J Health Serv Res Policy 2, 112-121.
21. Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B (2006) Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 4, 312-319.
22. Williams LR, Hutchinson CE, Jackson A, Horan MA, Jones M, McInnes L, Rabbitt PM, Pendleton N (2010) Clinical correlates of cerebral white matter hyperintensities in cognitively normal older adults. Arch Gerontol Geriatr 2, 127-131.
23. van Dijk EJ, Prins ND, Vermeer SE, Koudstaal PJ, Breteler MM(2002) Frequency of white matter lesions and silent lacunar infarcts. J Neural Transm Suppl 62, 25-39.
24. Wahlund LO, Julin P, Johansson SE, Scheltens P (2000)Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: A comparative study. J Neurol Neurosurg Psychiatry 5, 630-635.
25. van de Pol LA, Korf ES, van der Flier WM, Brashear HR, Fox NC, Barkhof F, Scheltens P (2007) Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 7, 1023-1028.
26. van de Pol LA, van der Flier WM, Korf ES, Fox NC, Barkhof F, Scheltens P (2007) Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 15, 1491-1497.
27. Espinosa A, Alegret M, Valero S, Vinyes-Junqué G, Hernández I, Mauleón A, Rosende-Roca M, Ruiz A, López O, Tárraga L, Boada M (2013) A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J Alzheimers Dis 34, 769-780.
28. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 3, 270-279.
29. van Rossum IA, Vos S, Handels R, Visser PJ (2010) Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: Implications for trial design. J Alzheimers Dis 3, 881-891.